Malaysia MDA Medical Device Registration: How Should Multiple Models Be Grouped in One Submission?

Short answer: Malaysia's Medical Device Authority (MDA) does not require every model or variant to be filed as a separate registration. Multiple models can normally be grouped under a single registration when they form one device family or system: the same manufacturer and manufacturing site, the same risk class, the same intended purpose and mode of action, the same design and technology platform, and the same applicable standards, with the technical file, performance test reports, clinical evidence, risk management file and labelling covering every model in the group. Where models differ in intended use, risk class, technology, materials, sterilisation, energy source, software or IVD characteristics, they should be split into separate applications. Grouping should therefore be decided on the basis of a documented classification and documentation gap assessment, not on commercial similarity alone.

Published: 10 July 2026, 10:36  |  Updated: 10 July 2026, 10:36

This FAQ addresses the questions companies most frequently need to resolve first in international medical device registration, documentation preparation, compliance pathways and post-market maintenance. It is based on AIMEILI regulatory practice materials and publicly available regulatory information. Specific projects should follow the latest requirements of the target-country regulator and the actual product documentation base.

Key Takeaways

MDA registration dossiers in Malaysia are normally prepared around device classification, the technical file, ISO 13485 quality system evidence, performance verification, risk management, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents, and the appointment of a local representative. Companies should complete a documentation gap assessment first, then decide whether existing NMPA, CE or other market documentation can be reused.

For Chinese medical device manufacturers, the safer approach is to confirm product classification and document gaps before deciding whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Target-market registration typically affects the technical file, authorised representative, importer cooperation, labelling language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by a list of documents to submit, deficiencies and rework are likely in model coverage, evidence-chain consistency, label claims and certificate control.

AIMEILI recommends that companies plan this question within a broader GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets rather than rebuilding documentation from scratch for each country.

When This Applies and the Core Question

Companies searching for guidance on grouping multiple models for Malaysian registration are usually not looking for a conceptual explanation. They need to know whether their existing documentation can support a target-market submission, whether a local agent or authorised representative is required, why timelines are extended, and which issues could affect the launch plan. The question typically involves product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibilities at the same time.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America in parallel, answering the process question for one country alone is insufficient. A more valuable approach is to build reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling first, and then localise them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended purpose, mode of action, use environment, method and duration of body contact, whether the device is sterile, whether it is active, and whether it incorporates software or has IVD characteristics. Only then can the risk class and submission pathway be determined. If the pathway is wrong, all subsequent translation, notarisation, authorisation, testing and supplementary submissions will move in the wrong direction.

For a target-market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who initiates changes, and who maintains renewal documentation. If these points are left vague in a commercial contract, market control can be compromised later.

Documents and Evidence

Typical documentation includes the device description, model and specification matrix, intended purpose, risk classification rationale, ISO 13485 or applicable quality system evidence, the technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without restructuring the evidence according to the target-market pathway.
• Listing too many model variants while test reports, clinical evidence or labelling coverage is insufficient.
• Selecting a local agent purely on commercial sales terms, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, IFUs, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, causing duplicated work in every country and inflating both cost and timelines.

Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended purpose statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language IFUs.
• Confirm the duties, fees, certificate control and exit mechanisms of the local agent or authorised representative.
• Establish a target-country gap assessment table specifying what must be re-tested, translated, notarised or supported by additional declarations.

AIMEILI Perspective

AIMEILI advises companies not to view target-market registration as a one-off document submission, but to manage it as an overseas market access programme. For companies entering multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and more conducive to later changes and renewals than assembling documents country by country at short notice.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; third, the regulatory responsibility boundary of local partners. If these three items are unclear, a project may still face repeated rounds of deficiency responses, agent communication and post-market maintenance issues, no matter how extensive the documentation appears.

Frequently Followed-up Questions

Can domestic Chinese documentation be used directly for target-market registration?

Domestic documentation can serve as a basis, but it normally cannot be submitted as-is. Companies need to adjust the documentation structure, language, labelling, authorisation documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

As soon as the target markets and product list are confirmed. The earlier the gap assessment is completed, the easier it is to schedule additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in regulatory communication, changes, renewals and post-market event handling. Unclear responsibilities and rights can affect certificate control and long-term market stability.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project tracker that manages the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in one place. This allows documentation gaps to be identified promptly and enables management to judge whether the project will affect the launch plan.

Companies that already have registrations in several countries should also build an evidence reuse matrix, defining which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and IFUs, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm the target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarisation, testing and deficiency-response status.
• Plan post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a review perspective, quality system documentation is not an isolated certificate. Regulators typically check whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent. If the ISO 13485 certificate scope does not match the device being registered, or if the manufacturing address, model specifications or IFU version conflict with the test reports, a company may be asked for supplementary clarification even after preparing a large volume of documents.

Companies should build an evidence consistency checklist before submission, mapping device name, model specifications, intended purpose, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU versions, and quality system certificate item by item. This step appears basic, but it can significantly reduce the likelihood of deficiency letters, particularly for projects covering multiple GHWP member states or several product families submitted at the same time.

Localisation and Authorised Representative Responsibilities

Target-market registration projects usually involve arrangements for a local agent, authorised representative, importer or registration holder. Companies must confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, IFUs and authorisation documents cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation is converting reusable evidence into a submission structure acceptable in the target country, not writing an isolated new set of documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining a certificate but neglect post-market maintenance; when a manufacturing site change, model extension, IFU update or agent replacement occurs later, the certificate and commercial sales can easily become misaligned.

AIMEILI recommends managing this question within an annual international registration plan: define target-market priorities first, build a reusable documentation package and a country gap list, and then schedule submission, deficiency response, post-market maintenance and renewal milestones. The value lies not only in improving registration efficiency in a single country, but in helping the company build a repeatable overseas compliance capability and reduce the cost of starting from zero each time it enters a new market.

Further Reading

• What should be prepared before renewing a medical device registration in Malaysia?
• What are the risk management documentation requirements for medical device registration in Malaysia?
• How should registration documentation for Malaysia be prepared?
• How is product classification determined for medical device registration in Malaysia?
• How should the technical file be organised for medical device registration in Malaysia?
• How should labelling and instructions for use be localised for Malaysia?
• How should clinical evaluation documentation be prepared for Malaysia?
• Can test reports be reused for medical device registration in Malaysia?

Content Review and Scope of Application

Author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Source principles: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.
Scope of application: This article supports preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target-country regulator, testing conclusions or legal advice.